Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: Week 52 results from SPIRIT-P2
Genovese MC et al. Rheumatology (Oxford) 2018: key182. doi: 10.1093/rheumatology/key182
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.